器官移植免疫耐受的研究热点追踪

石炳毅; 许晓光

doi:10.13201/j.issn.1001-1420.2016.10.001

器官移植免疫耐受的研究热点追踪

石炳毅^,,
许晓光

- 解放军第309医院全军器官移植研究所,北京市器官移植和免疫调节重点实验室(北京,100091)
基金项目:
国家自然科学基金(编号81370578,81570680)

详细信息

作者简介:
石炳毅,主任医师、教授、博士生导师,第十届全国政协委员,获国务院政府特殊津贴、何梁何利科技进步奖和中国医师奖。现任解放军第三〇九医院全军器官移植研究所所长、国家临床重点专科军队建设项目负责人、北京市器官移植与免疫调节重点实验室主任,兼任中国人体器官捐献与移植委员会委员、中华医学会器官移植学分会候任主任委员(兼肾移植学组组长)、中国医师协会器官移植医师分会副会长(兼肾脏移植专业委员会主任委员)、中国研究型医院学会移植医学专业委员会主任委员、中国医疗保健国际交流促进会常务理事等学术职务。长期从事泌尿外科和器官移植的临床与科研工作,创建并推广肾脏移植关键技术体系,创新器官移植学科建设模式,组建集成化综合型器官移植中心,构建国家级肾移植数据平台,主持制定器官移植相关行业标准,推动了我国器官移植事业的规范化进程。先后承担国家863课题、科技支撑重大项目、全军科技攻关课题、国家自然科学基金课题20余项。以第一完成人获国家科技进步二等奖1项,中华医学科技一等奖2项,军队医疗成果一、二等奖,军队科技进步二等奖及北京市科技进步二等奖等5项,国家发明专利6项。主持建立"中国肾脏移植科学登记系统"、"中国肾脏移植质量控制中心"和"军队器官移植科学登记系统"等国家和军队级重点工程。主编国内行业标准《临床诊疗指南》和《临床技术操作规范》器官移植分册等专著9部,发表论文290余篇,其中SCI收录45篇,培养博士(后)、博士、硕士研究生72人。

通讯作者: 石炳毅,E-mail:shibingyi@medmail.com.cn

中图分类号: R392.4;R699.2

收稿日期: 2016-08-30

Research hotspots in transplantation tolerance

SHI Bingyi^,,
XU Xiaoguang

- Organ Transplantation Institute,the 309th Hospital of Chinese People’s Liberation Army,Beijing Key Laboratory of Organ Transplant and Immune Regulation，Beijing，100091, China

More Information

Corresponding author: SHI Bingyi, E-mail: shibingyi@medmail.com.cn

Received Date: 30 August 2016

摘要

摘要: 移植免疫耐受是临床器官移植的最高目标,随着其诱导方法和机制研究的逐步深入,临床免疫耐受的诱导也取得了诸多进展。本文拟简述近年来肾移植免疫耐受机制研究和临床诱导方案的发展变化,并对其今后研究的发展方向进行展望。
- 器官移植 /
- 免疫耐受 /
- 研究进展
Abstract: Transplantation tolerance is the ultimate goal of transplantation.With the development of the research on mechanisms and induction protocols,the clinical induction of transplantation tolerance has been made much progress recently.Here,the recent development of the mechanisms and clinical induction protocols of renal transplantation tolerance were introduced,and the future research direction was prospected.
- organ transplant /
- immune tolerance /
- research progress

HTML全文

参考文献(39)

[1]	Massart A,Pallier A,Pascual J,et al.The DESCARTES-Nantes survey of kidney transplant recipients displaying clinical operational tolerance identifies 35 new tolerant patients and 34 almost tolerant patients[J].Nephrol Dial Transplant, 2016,31(6):1002-1013.
[2]	Brouard S,Mansfield E,Braud C,et al.Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance[J].Proc Natl Acad Sci U S A,2007,104(39):15448-15453.
[3]	Bestard O,Cuñetti L,Cruzado J M,et al.Intragraft regulatory T cells in protocol biopsies retain foxp3 demethylation and are protective biomarkers for kidney graft outcome[J].Am J Transplant,2011,11(10):2162-2172.
[4]	Bestard O,Cruzado J M,Rama I,et al.Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts[J].J Am Soc Nephrol,2008,19(10):2020-2026.
[5]	Safinia N,Scotta C,Vaikunthanathan T,et al.Regulatory T cells:serious contenders in the promise for immunological tolerance in transplantation[J].Front Immunol,2015,6:438.
[6]	Braza F,Durand M,Degauque N,et al.Regulatory T cells in kidney transplantation:new directions[J].Am J Transplant,2015,15(9):2288-300.
[7]	Scalea J R,Tomita Y,Lindholm C R,et al.Transplantation tolerance induction:cell therapies and their mechanisms[J].Front Immunol,2016,7:87.
[8]	Kinder J M,Jiang T T,Ertelt J M,et al.Cross-generational reproductive fitness enforced by microchimeric maternal cells[J].Cell,2015,162(3):505-515.
[9]	Heidt S,Vergunst M,Anholts J D,et al.B Cell markers of operational tolerance can discriminate acute kidney allograft rejection from stable graft function[J].Transplantation,2015,99(5):1058-1064.
[10]	Durand J,Chiffoleau E.B cells with regulatory properties in transplantation tolerance[J].World J Transplant,2015,5(4):196-208.
[11]	Baron D,Ramstein G,Chesneau M,et al.A common gene signature across multiple studies relate biomarkers and functional regulation in tolerance to renal allograft[J].Kidney Int,2015,87(5):984-995.
[12]	Chesneau M,Michel L,Dugast E,et al.Tolerant Kidney Transplant Patients Produce B Cells with Regulatory Properties[J].J Am Soc Nephrol,2015,26(10):2588-2598.
[13]	Braza F,Soulillou J P,Brouard S.Gene expression signature in transplantation tolerance[J].Clin Chim Acta,2012,413(17-18):1414-1418.
[14]	Kim J I,Rothstein D M,Markmann J F.Role of B cells in tolerance induction[J].Curr Opin Organ Transplant,2015,20(4):369-375.
[15]	Flores-Borja F,Bosma A,Ng D,et al.CD19+ CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation[J].Sci Transl Med,2013,5(173):173ra23.
[16]	Nouël A,Simon Q,Jamin C,et al.Regulatory B cells:an exciting target for future therapeutics in transplantation[J].Front Immunol,2014,5:11.
[17]	Fuchs E J.Transplantation tolerance:from theory to clinic[J].Immunol Rev,2014,258(1):64-79.
[18]	Strober S.Use of hematopoietic cell transplants to achieve tolerance in patients with solid organ transplants[J].Blood,2016,127(12):1539-1543.
[19]	Kawai T,Sachs D H,Sprangers B,et al.Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression[J].Am J Transplant,2014,14(7):1599-1611.
[20]	Yolcu E S,Leventhal J R,Ildstad S T.Facilitating cells in tolerance induction for kidney transplantation[J].Curr Opin Organ Transplant,2015,20(1):57-63.
[21]	Leventhal J R,Elliott M J,Yolcu E S,et al.Immune reconstitution/immunocompetence in recipients of kidney plus hematopoietic stem/facilitating cell transplants[J].Transplantation,2015,99(2):288-298.
[22]	Leventhal J,Abecassis M,Miller J,et al.Update on phase 2clinical trial to induce tolerance in mismatched living donor renal transplant recipients[J].J Field Ornithol,2013,81(4):349-360.
[23]	Oura T,Hotta K,Cosimi A B,et al.Transient mixed chimerism for allograft tolerance[J].Chimerism,2015,6(1-2):21-26.
[24]	Leventhal J R,Mathew J M,Salomon D R,et al.Nonchimeric hla-identical renal transplant tolerance:regulatory immunophenotypic/genomic biomarkers[J].Am J Transplant,2016,16(1):221-234.
[25]	Yamashita K,Goto R,Zaitsu M,et al.Induction of operational tolerance by cell therapy using donor Agpulsed tregs in living donorliver transplantation[J].Transplantation,2014,6:6.
[26]	Todo S,Yamashita K,Goto R,et al.A pilot study of operational tolerance with a regulatory t cell-based cell therapy in living donor liver transplantation[J].Hepatology,2016,64(2):632-643.
[27]	Anon.2015 American transplant congress abstracts[J].Am J Transplant,2015,15 Suppl 3:S1.
[28]	Rostaing L P,Malvezzi P.HLA-incompatible kidney transplantation--worth the risk[J].N Engl J Med,2016,374(10):982-984.
[29]	Opelz G,Morath C,Süsal C,et al.Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction:results from 101centers[J].Transplantation,2015,99(2):400-404.
[30]	王显丁,邱阳,宋涂润,等.ABO血型不相容亲属活体肾移植的个体化预处理[J].中华器官移植杂志,2015,36(8):477-480.
[31]	王毅,罗志刚,桂培根,等.供、受者ABO血型不相容保留受者脾脏的亲属活体供肾移植一例[J].中华器官移植杂志,2007,28(11):694-695.
[32]	Orandi B J,Luo X,Massie A B,et al.Survival benefit with kidney transplants from HLA-incompatible live donors[J].N Engl J Med,2016,374(10):940-950.
[33]	Wongsaroj P,Kahwaji J,Vo A,Jordan SC.Modern approaches to incompatible kidney transplantation[J].World J Nephrol,2015,4(3):354-362.
[34]	Orandi B J,Garonzik-Wang J M,Massie A B,et al.Quantifying the risk of incompatible kidney transplantation:a multicenter study[J].Am J Transplant,2014,14(7):1573-1580.
[35]	Montgomery R A,Lonze B E,King K E,et al.Desensitization in HLA-incompatible kidney recipients and survival[J].N Engl J Med,2011,365(4):318-326.
[36]	Sarwal M M.Fingerprints of transplant tolerance suggest opportunities for immunosuppression minimization[J].Clin Biochem,2016,49(4-5):404-410.
[37]	Sawitzki B.Liver Transplant patients with operational tolerance:what can the graft itself tell us?[J].Am J Transplant,2016,16(4):1049-1050.
[38]	Brent L.Transplantation tolerance-a historical introduction[J].Immunology,2016,147(3):267-268.
[39]	Elias N,Cosimi A B,Kawai T.Clinical trials for induction of renal allograft tolerance[J].Curr Opin Organ Transplant,2015,20(4):406-411.